-+ 0.00%
-+ 0.00%
-+ 0.00%

HSBC Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $920

Benzinga·09/10/2026 13:38:33
Listen to the news
HSBC analyst Rajesh Kumar maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $800 to $920.